Skip to content

Oncomed: Bayer terminates licensing option

April 10, 2017

*Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept

* Oncomed – Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons

* Oncomed – Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics

* Oncomed Pharmaceuticals Inc – small molecule program under companies’ collaboration continues without change

* Oncomed – will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: